Canada must respond to U.S. policy by increasing our support for pharmaceutical innovation
Changing our own drug system to better encourage investment and innovation is not an easy task, but it's a necessary one.
Despite an endless slew of headlines caused by the United States administration’s drastic trade policy course changes over the past 12 months, one executive order from last May has largely flown under the radar. The White House has proposed benchmarking domestic drug price...
Get Weekend Point of View Newsletter
Top Canadian political and policy opinion and analysis. Saturdays and Sundays. Weekends.
By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy
